Download PDF
Onkologische Welt 2012; 03(04): 188-190
DOI: 10.1055/s-0038-1630217
ASCO – Uro-Onkologie
Schattauer GmbH

Prostatakarzinom: Klinischer Stellenwert der intermittierenden Androgenblockade in der Diskussion

Birgit Pohlmann
Further Information

Publication History

Publication Date:
01 February 2018 (online)

    Permissions and Reprints

Heftig diskutiert wurde auf dem diesjährigen Symposium „Best-of-ASCO Germany” der Stellenwert der intermittierenden Androgenblockade (IAD) bei Patienten mit hormonsensiblem fortgeschrittenem Prostatakarzinom.

 

  • Literatur

  • 1 Hussain M. et al. Intermittent vs. continuous androgen deprivation in hormone sensitive metastasic prostate cancer patients: results of S9346, an international phase III trial. J Clin Oncol 30. 2012 (suppl); Abstract 4.
    Google Scholar
  • 2 Moinpour C. et al. Preliminary quality-of-life outcomes for SWOG-9346: Intermittent AD in patients with hormone-sensitive mPC - Phase III (HSM1PC). J Clin Oncol 2012; 30 (suppl.): Abstract 4571.
    Google Scholar
  • 3 Ryan C. et al. Interim analysis results of COU-AA-302, a randomized phase III study of Abiraterone acetate in chemotherapy-naive patients with metastatic castrtations-resistant prostate cancer). J Clin Oncol 2012; 30 (suppl.): Abstract LBA4518.
    CrossrefGoogle Scholar
  • 4 de Bono J. et al., Primary, secondary and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor). J Clin Oncol 2012; 30 (suppl.): Abstract 4519.
    Google Scholar
  • 5 Parker C. et al. Final overall survival analysis results from the phase III, double-blind, randomized multinational study of radium-223 chloride in the treatment of patients with castration-resistent prostate cancer with bone metastases). J Clin Oncol 2012; 30 (suppl): Abstract LBA4512.
    CrossrefGoogle Scholar